Mr. Michael Cola reports

HELUS PHARMA STRENGTHENS MEDICAL LEADERSHIP BY APPOINTING DR. KEN KRAMER AS SENIOR VICE PRESIDENT, MEDICAL AFFAIRS

Cybin Inc. (Helus Pharma) has appointed Dr. Ken Kramer, PhD, as senior vice-president, medical affairs, effective immediately.

Dr. Kramer joins Helus with more than two decades of experience leading medical affairs strategy across neuroscience programs, including global launch readiness, evidence generation and engagement with key opinion leaders. Most recently, he served as vice-president and head of medical neuroscience at Bristol Myers Squibb, where he led an integrated medical strategy team to successfully launch the first new treatment for schizophrenia in over seven decades.

"Strong medical leadership is vital to how we connect with and serve the scientific and clinical communities," said Michael Cola, chief executive officer of Helus Pharma. "Dr. Kramer brings both deep experience and an execution mindset to help us scale medical capabilities and advance our pipeline. His leadership will be instrumental in translating strong science into meaningful engagement with patients, providers and payors."

At Karuna Therapeutics, as VP and head of medical affairs, Dr. Kramer built and expanded medical capabilities during a period of significant organizational growth and supported the organization through its acquisition. Earlier in his career, Dr. Kramer spent more than a decade leading U.S. psychiatry medical affairs teams at AbbVie and its predecessor organizations, contributing to multiple successful product launches. He began his career in academic medicine as an assistant professor of psychiatry.

"Throughout my career in psychiatry, I've been driven by the profound unmet needs of patients and families affected by serious mental health conditions," said Dr. Kramer. "Helus is driving innovation in its field through the strength of its science and its commitment to advancing NSAs [novel serotonergic agonists] as a differentiated approach to treating complex neuropsychiatric disorders. Joining Helus at this stage, where strong medical leadership can deepen scientific engagement and further evolve the organization's medical capabilities, is incredibly meaningful to me. I look forward to collaborating across Helus to translate their innovative science into meaningful understanding for clinicians and, ultimately, better outcomes for patients."

Dr. Kramer holds a PhD in neuropharmacology from New York University and a master of science in neuroscience and a bachelor of science in biology from the University of Rochester.

About Cybin Inc. (Helus Pharma)

Helus Pharma, the commercial operating name of Cybin, is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs -- novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company's proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety and other mental health conditions.

We seek Safe Harbor.